UniPrint.net Acquires ePRINTit USA Inc.
UniPrint.net announced today that it has acquired cloud printing solutions provider ePRINTit™, a wholly owned subsidiary of St. Joseph Printing Group Inc., whose cloud/mobile pull printing solution leads the world in publicly accessible printers.
ePRINTit™ adds easily accessible, cloud-based, embedded technology to their global partner, Hewlett Packard (HP Inc.), allowing for self-service scanning, printing, and mobile payments from-anywhere to-anywhere.
Together, ePRINTit™ and HP’s ePrint™ have over 15 Million mobile app downloads and embedded print driver technology in over 100 Million PCs globally. Customers can securely send their documents to geo-located printers in places such as FedEx and UPS retail storefronts, post offices, convenience stores, colleges, and universities. Spanning over 140 countries, ePRINTit’s shared economy model allows users, who submit over 20 documents per second, to print to a global network of over 28,000 locations.
With over 11 Billion iOT connected devices and over 2.1 Billion smartphone users globally in 2017, everyone is connecting to the new secure Cloud and Edge data centers. Behind every product, every app, and every device there is a customer. As the world quickly adopts a shared economy model focusing and positively affecting the environment, printing technology also shifts from a luxury based home product to a shared economy model.
UniPrint.net Managing Partner and CEO David Fung believes his organization’s added support and resources, combined with their established enterprise and cloud printing solutions, will allow the industry’s evolution and growth to dramatically accelerate:
“While our software, UniPrint Infinity™, primarily serves businesses and organizations such as hospitals, banks, and government offices, ePRINTit™ allows our customers to print securely from their private PCs or mobile devices and release it to an ePRINTit™ public print location without any security concerns. Together we truly offer an end-to-end secure print solution for anyone in any environment.”
About UniPrint.net Corp.
UniPrint.net Corp. is an innovative leader in printing virtualization. Their patented PDF-based software UniPrint Infinity™ is the industry’s first truly secure enterprise printing solution for any computing environment. UniPrint Infinity™ replaces all manufacturer printer drivers with a single Universal Printer Driver (UPD) to promote faster, more efficient printing. Both UniPrint™ and UniPrint Infinity™ are the trademarks of UniPrint.net. All other trademarks and registered trademarks are properties of their respective owners.
About ePRINTit ™
ePRINTit™ is the world’s most powerful cloud print platform that is revolutionizing how businesses and education acquire and engage their customers as they live, work and play on-the-go™. ePRINTit™ allows print to be securely processed from-anywhere to-anywhere, enabling users to print from any web-enabled device, chose the closest print location and select their payment preferences. It’s a self-service, fully managed communications system available 24/7, connecting web-enabled Internet devices with technology around the world.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180110005759/en/
Contact information
UniPrint.net Corp.
Kate Bradford
Marketing Specialist
416-503-9800
x8258
kate.bradford@uniprint.net
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom